Guardant Health Stock Price, News & Analysis

Guardant Health, Inc. (Nasdaq: GH) reported Q1 2022 revenue of $96.1 million, a 22% increase from the previous year. Clinical testing volumes surged 47% and biopharma volumes rose 45%. Gross profit reached $64.1 million, with a gross margin of 67%. However, operating expenses also increased by 19% to $187.5 million, leading to a net loss of $123.2 million for the quarter. The company maintains guidance for full-year 2022 revenue of $460 million to $470 million, reflecting 23% to 26% growth.

Fanatics has appointed Lydia Jett and Jonathan Mildenhall to its board of directors, bringing extensive experience from fintech, e-commerce, and marketing sectors. Jett, from SoftBank, played a crucial role in Fanatics' growth since their initial $1 billion investment in 2017. Mildenhall, former CMO of Airbnb, is noted for transforming brand strategies. Both directors will guide Fanatics in expanding its diverse portfolio, which includes licensed merchandise, digital collectibles, and online sports betting. Additionally, Fanatics released its first ESG report, highlighting its commitment to sustainability and social responsibility.

Guardant Health has launched Shield, a blood-based test aimed at early-stage colorectal cancer (CRC) detection, targeting adults aged 45 and older who are not current with screening guidelines. The test boasts a sensitivity of 91% for CRC and 20% for advanced adenomas with a specificity of 92%. This innovative screening method addresses compliance barriers associated with traditional methods like colonoscopy, offering a simple blood draw with no preparation required. Shield is now available by prescription through healthcare providers.

Guardant Health, a leading precision oncology firm, will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas on May 10. The management team is set to engage in a fireside chat at 10:40 a.m. Pacific Time. Investors can access a live and archived webcast through the company’s website. Guardant Health focuses on revolutionizing cancer care with proprietary tests like Guardant360 and Guardant Reveal, aiming to enhance patient outcomes and reduce healthcare costs.

Guardant Health (Nasdaq: GH) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call for investors will follow at 1:30 p.m. PT / 4:30 p.m. ET. The call can be accessed via the company’s website, where an archive will be available post-event. Guardant Health specializes in precision oncology, offering advanced tests for cancer patients and driving initiatives to improve clinical outcomes and reduce healthcare costs.

Guardant Health (NASDAQ: GH) announced promising data from its investigational Guardant SHIELD multi-cancer assay. This blood test analyzes approximately 20,000 epigenomic biomarkers to detect early-stage cancers, specifically colorectal, lung, pancreatic, and bladder cancers, which account for over 200,000 deaths annually in the U.S. The assay demonstrated a 90% sensitivity for stages I and II colorectal cancer and 87% for lung cancer, with high accuracy in identifying tumor tissue types. These results suggest potential to significantly improve cancer screening rates and save lives.

Guardant Health has announced a partnership with Epic, enhancing access to its cancer tests for over 250 million patients. This integration allows healthcare providers to electronically order Guardant tests, including Guardant SHIELD for colorectal cancer screening, and access results seamlessly. The collaboration aims to simplify workflows for clinicians, improving patient care by ensuring quick access to critical test results. The integration is expected to be completed in Q3 2023, promoting the adoption of Guardant's precision oncology offerings across diverse healthcare settings.

Guardant Health (Nasdaq: GH) responded to a lawsuit from Illumina challenging its ownership of intellectual property related to blood tests. Guardant claims the lawsuit is an attempt to suppress competition, following its concerns about the antitrust implications of Illumina's acquisition of Grail. Despite legal challenges, Guardant remains committed to its mission of developing cancer screening tests. The company maintains that their long-term supply agreement with Illumina is intact and that they will vigorously defend their intellectual property rights.

Guardant Health, Inc. (Nasdaq: GH) has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare for its Guardant360® CDx test, which profiles tumor mutations in patients with advanced solid tumors. The test will identify patients with microsatellite instability-high (MSI-High) tumors eligible for Keytruda® and Opdivo®. This approval enhances the company's commitment to improving cancer care through innovative blood-based diagnostics, following a prior approval for NSCLC in December 2021.